Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.

The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.

Study Overview

• Status: Completed
• Conditions: Actinic Keratosis
• Intervention / Treatment: Drug: PEP005

Detailed Description

Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.

• Study Type: Interventional
• Enrollment: 200
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Huntsville, Alabama, United States, 35801
      • Medical Affiliated Research Center, Inc.
  • Arizona
    • Tucson, Arizona, United States, 85710
      • Radiant Research
  • Arkansas
    • Hot Springs, Arkansas, United States, 71913
      • Burke Pharmaceutical Research
  • Florida
    • Clermont, Florida, United States, 34711
      • Advanced Dermatology and Cosmetic Surgery
    • Coral Gales, Florida, United States, 33134
      • Dermatology Associates and Research
    • Jacksonville, Florida, United States, 32204
      • North Florida Dermatology Associates P.A.
    • Orange Park, Florida, United States, 32073
      • Park Avenue Dermatology, PA
    • Tallahassee, Florida, United States, 32308
      • Dermatology Associates of Tallahassee
    • West Palm Beach, Florida, United States, 33401
      • Palm Beach Aesthetics
  • Georgia
    • Newnan, Georgia, United States, 30263
      • MedaPhase, Inc
    • Snellville, Georgia, United States, 30078-3250
      • Gwinnett Clinical Research Centre, Inc
  • Michigan
    • West Bloomfield, Michigan, United States, 48322
      • Henry Ford Health Center- Farmington Road
  • New Mexico
    • Albuquerque, New Mexico, United States, 87106-5239
      • Academic Dermatology Associates
  • New York
    • New York, New York, United States, 10025
      • St. Luke's/Roosevelt Hospital Center Dermatology
    • New York, New York, United States, 10029
      • Mount Sinai Hospital School of Medicine
  • Ohio
    • Cincinnati, Ohio, United States, 45219-4215
      • University Dermatology Consultants, Inc., Dermatology Clinical Research Center
    • Columbus, Ohio, United States, 43212
      • Radiant Research
  • Oregon
    • Centre9495 SW Locust St., Suite G Portland, Oregon, United States, 97223
      • Oregon Medical Research
  • South Carolina
    • Anderson, South Carolina, United States, 29621
      • Radiant Research
    • Greer, South Carolina, United States, 29651
      • Radiant Research
  • Texas
    • San Antonio, Texas, United States, 78229-3409
      • Dermatology Clinical Research Center of San Antonio
    • Tyler, Texas, United States, 75703
      • Dermatology Associates of Tyler
  • Utah
    • Salt Lake City, Utah, United States, 84124
      • Dermatology Research Centre
  • Washington
    • Spokane, Washington, United States, 99204
      • Skokane Dermatology Clinic, PLLP.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion

1. Male patients at least 18 years of age.
2. Post-menopausal female patients i.e., no menses for at least 12 consecutive months, or without a uterus.
3. 4 to 8 clinically typical, visible and discrete AK lesions within a contiguous 25 cm2 treatment area on the arm, shoulder, chest, back or scalp.
4. Screening laboratory values within the reference ranges as defined by the central laboratory or "out of range" test results that are clinically acceptable to the Investigator.
5. Ability to follow study instructions and likely to complete all study requirements.
6. Written informed consent has been obtained.
7. Written Authorization for Use and Release of Health and Research Study Information has been obtained.
8. Agreement from the patient to allow photographs of the selected AK treatment area to be taken and used as part of the study data package.

Exclusion

1. Females of child bearing potential (a female is considered of childbearing potential unless she is postmenopausal, i.e., no menses for at least 12 consecutive months, or is without a uterus).

2. Location of the selected AK treatment area:

   1. anywhere on the face
   2. within 5 cm of an incompletely healed wound
   3. on the breast area of women
   4. on the dorsum of the hand
3. AK lesions that have atypical clinical appearance e.g. hypertrophic, hyperkeratotic, recalcitrant disease (had cryosurgery on 2 previous occasions), cutaneous horns within the selected AK treatment area.
4. Presence of suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) within the selected AK treatment area or within 10 cm of the selected AK treatment area.
5. Presence of known or suspected metastatic disease.
6. History or evidence of skin conditions other than AK that would interfere with evaluation of the study drug (e.g. eczema, unstable psoriasis, xeroderma pigmentosa).
7. Known sensitivity to any of the ingredients in the study drug.

8. A cosmetic or therapeutic procedure (e.g. use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing):

   • within 2 cm of the selected AK treatment area during the 4 weeks prior to screening visit

9. Treatment with 5-fluorouracil, imiquimod, diclofenac, masoprocol or photodynamic therapy:

   • within 2 cm of the selected AK treatment area during the 24 months prior to screening visit or
   • anywhere during the 4 weeks prior to screening visit

10. Treatment with other immunomodulators (e.g. vinblastine, podophyllin, colhamin, camptothecin), cytotoxic drugs (e.g. cyclophosphamide, azathiopine, chlorambucil, nitrogen mustard, methotrexate), or interferon/ interferon inducers:

    • within 4 weeks prior to screening visit

11. Use of acid-containing therapeutic products (e.g. salicylic acids or fruit acids, such as alpha and beta hydroxy acids and glycolic acids), topical retinoids or light chemical peels:

    • within 2 cm of the selected AK treatment area during the 4 weeks prior to screening visit

12. Treatment with psoralen plus UVA (PUVA) or use of UVB therapy:

    • anywhere during the 6 months prior to screening visit

13. Use of systemic retinoids (e.g. isotretinoin, acitretin, bexarotene):

    • within 6 months prior to screening visit
14. Anticipated excessive or prolonged exposure to ultraviolet light (e.g. sunlight, tanning beds).

15. Use of topical salves, artificial tanners or topical steroids:

    • On the selected AK treatment area during the 4 weeks prior to screening visit
16. Anticipated need for hospitalization (in-patient) or surgery (except that specified in exclusion criteria 8) during the study.
17. Concurrent disease that suppresses the immune system (e.g. HIV, hepatitis).
18. Uncontrolled systemic disease (e.g. uncontrolled hypertension [a systolic blood pressure of 180 mmHg or greater and/or a diastolic blood pressure of 110 mmHg or greater], poorly controlled diabetes [fasting blood sugar of 350 mg/dl or greater]).

19. Use of systemic medications that suppress the immune system (e.g. cyclosporine, prednisone, methotrexate, alefacept, infliximab):

    • within 4 weeks prior to screening visit
20. Current evidence of chronic alcohol or drug abuse.
21. Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study or entry into another investigational drug or device study while enrolled in this study.
22. A condition or situation which in the Investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study [e.g. patients who required hospitalization in the 2 months prior to screening for an acute or chronic condition].
23. Selected AK treatment area within 5 cm of an AK lesion previously treated with PEP005, for those patients who have participated in earlier PEP005 topical gel trials. Patients enrolled in Treatment Phase 1 can not be re-enrolled into Treatment Phase 2.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Safety

Secondary Outcome Measures

Outcome Measure
Resolution of AK

Collaborators and Investigators

• Sponsor: Peplin
• Investigators: Principal Investigator: Lawrence Anderson, Dr; Study Chair: Peter Welburn, PhD, Sponsor GmbH

Publications and helpful links

Helpful Links

• Sponsor website

Study record dates

Study Major Dates

• Study Start: September 1, 2006
• Primary Completion (Actual): June 1, 2007
• Study Completion (Actual): June 1, 2007

Study Registration Dates

• First Submitted: September 11, 2006
• First Submitted That Met QC Criteria: September 11, 2006
• First Posted (Estimate): September 13, 2006

Study Record Updates

• Last Update Posted (Estimate): January 28, 2016
• Last Update Submitted That Met QC Criteria: January 26, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Keywords: Actinic Keratosis; Dermatology; Topical; Solar Keratosis; Sun Spots
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Precancerous Conditions; Keratosis, Actinic; Keratosis
• Other Study ID Numbers: PEP005-006

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No